This product is for Professional Use only and not for sale to the general public for home use.
Please log in with a business account to purchase.
Beta secretase inhibitor KMI-1072 Alzheimer's Disease Research Wako
Product code: 119-00921
Pack Size: 1mg
CE Verified: Research Use Only
Contact us
This is not a regular stock item and therefore not subject to our standard delivery schedule. Please contact us on +44 (0) 2380 483000 for advice on expected delivery date.
Product Information
KMI-1027 produced by FUJIFILM Wako Chemical Corporation
Amyloid precursor protein (APP) is an integral membrane protein expressed in many tissues with concentrated expression in neuron synapses. Whilst it's primary function is uncertain it is best known as the precursor of Aβ which accumulates in the brains of Alzheimer's sufferers. APP is subject to cleavage by the proteolytic secretase enzymes (ɑ-, β - and γ-secretase).
The predominant processing pathway for APP is proteolysis by ɑ-secretase, because this cleaves APP within the fragment that gives rise to Aβ, the ɑ-secretase pathway precludes Aβ formation. Cleavage of APP by β–secretase (also known as β–site APP Cleaving enzyme 1 or BACE1) results leaves a membrane bound fragment known as C99 which following the action of γ–secretase produces Aβ. This has led to interest in β -secretase inhibitors which might prevent or slow the build-up of Aβ and be of therapeutic use in the management of Alzheimer's disease.
KMI-1072 is a non-peptide β-secretase inhibitor produced by introducing a heterocyclic ring into the leucine part and a five-membered ring in the valine part of KMI-429 as the lead compound.
KMI-1072 1mg
IC50 = 50 nmol/L.
Molecular Formula=C33H29N7O7
Molecular Weight:635.63
CAS: 1022893-09-9
Store at -20°C
For cell biology
Research Use Only (RUO) - not for administration to humans.
Amyloid precursor protein (APP) is an integral membrane protein expressed in many tissues with concentrated expression in neuron synapses. Whilst it's primary function is uncertain it is best known as the precursor of Aβ which accumulates in the brains of Alzheimer's sufferers. APP is subject to cleavage by the proteolytic secretase enzymes (ɑ-, β - and γ-secretase).
The predominant processing pathway for APP is proteolysis by ɑ-secretase, because this cleaves APP within the fragment that gives rise to Aβ, the ɑ-secretase pathway precludes Aβ formation. Cleavage of APP by β–secretase (also known as β–site APP Cleaving enzyme 1 or BACE1) results leaves a membrane bound fragment known as C99 which following the action of γ–secretase produces Aβ. This has led to interest in β -secretase inhibitors which might prevent or slow the build-up of Aβ and be of therapeutic use in the management of Alzheimer's disease.
KMI-1072 is a non-peptide β-secretase inhibitor produced by introducing a heterocyclic ring into the leucine part and a five-membered ring in the valine part of KMI-429 as the lead compound.
KMI-1072 1mg
IC50 = 50 nmol/L.
Molecular Formula=C33H29N7O7
Molecular Weight:635.63
CAS: 1022893-09-9
Store at -20°C
For cell biology
Research Use Only (RUO) - not for administration to humans.
Specification
- Brand FUJIFILM Wako Chemicals Europe GmbH – Lab Chem
- Sterile N
- CE Certified Research Use Only
- Warranty Period Standard Terms Apply
- Is product classified as dangerous goods? No
- Does the product contain latex? Unspecified
- Source Species NULL
- CAS Number 1022893-09-9
- Application cell biology
- Molecular Formula C33H29N7O7
- Form 1mg
- Concentration NULL
- Purity NULL
- Marketed Grade Cell biology
- Molecular Weight 635.63
- Shelf Life NULL
- Species Reactivity NULL
- Preparation Form White-brown crystals
Storage Details
- Pack Description 1mg
- Shipping Condition Dry Ice
- Storage Condition -20
- Pack Length (m) 0.03
- Pack Width (m) 0.03
- Pack Height (m) 0.1
- Pack Weight (kg) 0.00